Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 2 | FLORENCE INDIA | 2 | ₹48.3 L |
| 2 | Schedule 3 | FLORENCE INDIA | 2 | ₹67.2 L |
| 3 | Schedule 4 | FLORENCE INDIA | 1 | ₹19.3 L |
| 4 | Schedule 5 | FLORENCE INDIA | 1 | ₹61.9 L |
| 5 | Schedule 6 | Not yet disclosed by govt. | 37 | - |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
5 Mar 2025, 1:00 pmClosed
Inj Degludec 100 IU SLACE ml 3 ml Pen
Human Insulin Analogue Glargine Inj
100 IU SALCE ml Recombinant DNA origin 300IU Disposable Pen with 5 needles per pen
Human Insulin Analogue Rapid acting Inj
100 IU SLACE ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen
Free Style Libre Reader With Sensor
Glucose Strip for Glucometer bottle of 100
Tab Sitagliptin 50mg
Testosterone propionate 250 mg Inj
Tab Sitagliptin 50 mg PLUS Metformin 1000 mg
Bleomycin Sulphate SALCE Chloride 15mg Inj
Tab Cabozantinib 40 gm
Tab Cabozantinib 60 gm
Bevacizumab 100 mg4ml vial
Inj
Inj Bevacizumab 300 mg
Inj Brentuximab Vedotin 50 mg
Pemetrexed 500mg powder for injection
Inj Pemetrexed 100 mg
Vincristine Sulphate 1mg Inj
Cyclophosphamide 500 mg Inj
Ifosfamide Inj 1g vial with 3 amp of 2 ml each Mesna
Tab Dacomitinib 30 mg Bottle of 30 Tab
Carboplatin 450mg Inj
Inj Denosumab 120 mg
Temozolamide 100mg Cap
Inj avelumab 200 mg SALCE 10ml
Inj Eribulin vial of 1 mg
Etoposide 100mg
5 ml Inj
Pegylated Liposomal Doxorubicin 20mg Inj
Irinotecan 100mg Inj
Gemcitabine 1000mg Inj
Gemcitabine 200mg Inj
inj TPGS Docetaxel 20 mg
inj TPGS Docetaxel 80 mg
inj TPGS Docetaxel 120 mg
Docetaxel 80mg SLACE 2ml vial 6 ml solvent for Inj
Docetaxel 20mg 0.5ml vial PLUS 1.5 ml Solvent for Inj
Erlotinib 150 mg Tab
Lenvatinib 4 mg tab
Lenvatinib 10 mg tab
Actinomycin D 0.5 mg Inj
5-Fluorouracil 500mg
10 ml Inj
Gefitinib 250mg Tab
Trabectadin 1mg powder for Inj
Inj Pegylated Liposomal Irinotecan 4.3mg SLACE ml
Tab ruCaparib 200 mg
Rucaparib 300 mg Tab
Inj Atezolizumab
vial of 1200 mg Bid Number ( ) : GEM/2024/B/5752218 Dated : 12-02-2025 Bid Document 1/43
7300214
GEM/2024/B/5752218
Two Packet Bid
Tab Cabozantinib 40 gm
30 days
West Bengal; Kolkata
Item wise evaluation
BOQ
7 documents required · 7 mandatory
2 yrs
₹3
20%
Exempted
5 Mar 2025
12 Feb 2025
5 Mar 2025
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|
| 1 | Inj Degludec 100 IU SLACE ml 3 ml Pen | 2,172 | Pen | Consignee2DGLP | 30 |
| 2 | Human Insulin Analogue Glargine Inj, 100 IU SALCE ml Recombinant DNA origin 300IU Disposable Pen with 5 needles per pen | 10,716 | Pen | Consignee2DGLP | 30 |
| 3 | Human Insulin Analogue Rapid acting Inj, 100 IU SLACE ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen | 11,130 | PFS | Consignee2DGLP | 30 |
| 4 | Free Style Libre Reader With Sensor | 186 | No | Consignee2DGLP | 30 |
| 5 | Glucose Strip for Glucometer bottle of 100 | 5,382 | Bottle | Consignee2DGLP | 30 |
| 6 | Tab Sitagliptin 50mg | 1,38,780 | No | Consignee2DGLP | 30 |
| 7 | Testosterone propionate 250 mg Inj | 150 | Amp | Consignee2DGLP | 30 |
| 8 | Tab Sitagliptin 50 mg PLUS Metformin 1000 mg | 1,39,800 | No | Consignee2DGLP | 30 |
| 9 | Bleomycin Sulphate SALCE Chloride 15mg Inj | 33 | AMP VIAL | Consignee2DGLP | 30 |
| 10 | Tab Cabozantinib 40 gm | 300 | No | Consignee2DGLP | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7300214.pdf
GEM_BID
atcpdf_2024-12-26-12-10-11_5ba9579ad6a1b689fada3e5a063014b8.pdf
BOQ
boq_item_2024-12-26-12-10-11_9875f6ca53111e5bf67e5841888998a0.csv
BOQ
Origin_9018f281-92be-4da2-b5bb1735195760729_buyer12chec.docx
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .